Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2025 07:00 ET | Source: Sitryx Therapeutics

Sitryx presents new preclinical data highlighting MTHFD2 as a novel metabolic target in autoimmune disease at ACR Convergence 2025

Preclinical data highlight MTHFD2 as a promising metabolic target in autoimmune disease, providing strong validation for the advancement of SIT-047, Sitryx’s MTHFD2 inhibitor program, into clinical...
October 16, 2025 04:27 ET | Source: Research and Markets

OX40 Targeted Therapies Clinical Trials and Market Opportunity Report 2026 | First OX40 Therapy Approval Expected by 2030

Dublin, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The "OX40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026" report has...
October 15, 2025 07:00 ET | Source: Sitryx Therapeutics

Sitryx to participate in upcoming investor conferences

Oxford, UK and Boston, MA – October 15, 2025 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune...
October 14, 2025 08:00 ET | Source: Tr1X, Inc.

Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing

Tr1X announced the FDA has cleared its IND application for TRX319 in progressive multiple sclerosis and a $50M financing that extends its runway into 2027.
October 02, 2025 07:00 ET | Source: Sitryx Therapeutics

Sitryx receives FDA clearance of IND application for SYX-5219 for the treatment of atopic dermatitis

SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission across a range of autoimmune diseasesPhase 1b trial to investigate the safety, tolerability and initial...
September 08, 2025 07:00 ET | Source: Sitryx Therapeutics

Sitryx appoints Adam Mostafa as Chief Financial Officer

Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK...
September 02, 2025 06:00 ET | Source: Upstream Bio

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Positive top-line results for VIBRANT Phase 2 clinical trial of verekitug in CRSwNP with once every 12 week dosing
September 01, 2025 17:00 ET | Source: Upstream Bio

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio to Host Conference Call/Webcast to Report Top-Line Data from Phase 2 VIBRANT Trial of Verekitug in Patients with CRSwNP
August 20, 2025 11:33 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics Awarded Second FDA Fast Track Designation for Recombinant Human Gelsolin to Treat Inflammasome-Driven Decompression Sickness (DCS)

Fast Track status accelerates regulatory pathway for BioAegis’ recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. Second Fast Track designation in...
May 07, 2025 04:03 ET | Source: Research and Markets

Chronic Spontaneous Urticaria Market Report 2025-2035: Industry Growth Accelerates with Rise in Biologic Therapies and Diagnostic Advancements

Dublin, May 07, 2025 (GLOBE NEWSWIRE) -- The "Chronic Spontaneous Urticaria Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report...